secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001628280-25-041043
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius-Decoy merger update: legacy holders ~7.6% stake, $6M minimum financing required
--------------------------------------------------------------------------------

- Step one: Decoy stockholders receive ~92.4% of Salarius; legacy holders ~7.6% based on exchange ratio.
- Merger closing conditioned on minimum $6.0M Qualified Financing and continued Nasdaq listing.
- Step two requires stockholder approval for Preferred Stock conversion; Nasdaq initial listing must precede.
- Decoy's lead pan-coronavirus prophylactic IND planned H1 2026; funded by Gates Foundation and BARDA.
- Combined company to explore P-PROTACs using Salarius' SP-3164, initial focus on metastatic colorectal cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000162828025041043/0001628280-25-041043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000162828025041043/flks-20250822.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-041043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer